This study is currently not recruiting participants.

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (CLEAN-PCD)

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

This purpose of this study is to test a new, inhaled medication that is designed to improve airway hydration and help with the clearance of mucus for individuals with Primary Ciliary Dyskinesia (PCD), a rare genetic condition affecting the lungs and other organs.

The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of these treatments on quality of life (QOL) in partipants with primary ciliary dyskinesia (PCD).

Description

The purpose of this study is to learn more about the safety and effects of the inhaled combination of VX-371 with and without hypertonic saline in patients with PCD.

Details
Condition primary ciliary dyskinesia
Age 12years - 100years
Clinical Study IdentifierTX6401
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.